Trial Profile

A Phase I Trial to Determine the Maximum Tolerated Dose and Patient-specific Dosimetry of Fractionated Intracavitary Radioimmunotherapy with Lu-177 Labeled 6A10 Fab-fragments in Patients with Glioblastoma After Standard Treatment

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Jun 2026 According to ITM Isotope Technologies Munich SE media release, Preliminary pilot data were published in EJNMMI Research (2023), demonstrating the feasibility and safety of intracavitary administration of [177Lu]6A10-Fab fragments in patients with glioblastoma.
29 Jun 2026 According to ITM Isotope Technologies Munich SE media release, Dr. Michael Muther, is the study investigator.
29 Jun 2026 According to ITM Isotope Technologies Munich SE media release, data from the trial were presented at the Nuclear Medicine and Neuro-Oncology (NMN) Society Annual Symposium, in Vienna, Austria.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com